CNX acquires four cancer drugs from Clinigen
The purchased therapies concerned are Cardioxane, Totect, Ethyol and Savene
Read More
Tag: CNX
CNX embarks on buy-and-build strategy
Investment is a key boost to the acceleration of treatment access in the UK
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
